March 31, 2020 10:32 AM EDTUpdated 02:41 PM

Myovant grabs $40M upfront in regional deal for relugolix; Akero announces NASH success but Covid-19 delays

ENDPOINTS

→ Having just filed for the European approval of its uterine fibroids drug relugolix, Myovant has sold the regional rights off to Hungarian biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Myovant grabs $40M upfront in regional deal for relugolix; Akero announces NASH success but Covid-19 delays

ENDPOINTS

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Novo Nordisk claims late-stage MASH victory, continuing GLP-1's expansion

Biogen brings in medical chief as CFO plans retirement; MacroGenics CEO announces departure

Exclusive: Blood stem cell therapy maker Garuda gets new CEO, adds $47M

FDA removes hold on three CARsgen CAR-T trials; Ono passes on itolizumab

Exclusive: Women’s health unicorn Maven Clinic cuts 10% of its workforce weeks after raising $125M

Baxter pulls IV products out of China to shift supply to the US

My­ovant grabs $40M up­front in re­gion­al deal for re­l­u­golix; Akero an­nounces NASH suc­cess but Covid-19 de­lays

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Myovant grabs $40M upfront in regional deal for relugolix; Akero announces NASH success but Covid-19 delays